Stocks to invest in – 13D Filing: Sarissa Capital Management and Novelion Therapeutics Inc. (NVLN)

Stocks to invest in

You can access the original SEC filing by clicking here.


Alex Denner

Sarissa Capital Management

Page 1 of 3 – SEC Filing

Washington, D.C. 20549


Under the Securities Exchange Act of 1934

(Amendment No. 2)*

Novelion Therapeutics Inc.

(Name of Issuer)

Common Stock, without par valuse

(Title of Class of Securities)


(CUSIP Number)

Mark DiPaolo

General Counsel

Sarissa Capital Management LP

660 Steamboat Road

Greenwich, CT 06830


With a copy to:

Russell Leaf

Willkie Farr & Gallagher LLP

787 Seventh Avenue

New York, New York 10019


(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

August 1, 2017

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐

Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See Rule 13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be  subject to all other  provisions of the Act  (however, see the Notes).

Follow Novelion Therapeutics Inc. (NASDAQ:NVLN)

Trade (NASDAQ:NVLN) Now!

Stocks to invest in

Learn How To Be #1 on Google Results

Source link